133 related articles for article (PubMed ID: 30206323)
1. Microvascular endothelial function is impaired in patients with idiopathic hyperaldosteronism.
Kishimoto S; Matsumoto T; Oki K; Maruhashi T; Kajikawa M; Matsui S; Hashimoto H; Kihara Y; Yusoff FM; Higashi Y
Hypertens Res; 2018 Nov; 41(11):932-938. PubMed ID: 30206323
[TBL] [Abstract][Full Text] [Related]
2. Effect of aldosterone-producing adenoma on endothelial function and Rho-associated kinase activity in patients with primary aldosteronism.
Matsumoto T; Oki K; Kajikawa M; Nakashima A; Maruhashi T; Iwamoto Y; Iwamoto A; Oda N; Hidaka T; Kihara Y; Kohno N; Chayama K; Goto C; Aibara Y; Noma K; Liao JK; Higashi Y
Hypertension; 2015 Apr; 65(4):841-8. PubMed ID: 25624340
[TBL] [Abstract][Full Text] [Related]
3. Eplerenone improves endothelial function and arterial stiffness and inhibits Rho-associated kinase activity in patients with idiopathic hyperaldosteronism: a pilot study.
Kishimoto S; Oki K; Maruhashi T; Kajikawa M; Matsui S; Hashimoto H; Takaeko Y; Kihara Y; Chayama K; Goto C; Aibara Y; Yusoff FM; Nakashima A; Noma K; Liao JK; Higashi Y
J Hypertens; 2019 May; 37(5):1083-1095. PubMed ID: 30418321
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of Adrenalectomy and Eplerenone on Vascular Function in Patients with Aldosterone-producing Adenoma.
Kishimoto S; Oki K; Maruhashi T; Kajikawa M; Hashimoto H; Takaeko Y; Harada T; Yamaji T; Han Y; Kihara Y; Chayama K; Goto C; Yusoff FM; Nakashima A; Higashi Y
J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32818224
[TBL] [Abstract][Full Text] [Related]
5. Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism.
Ohno Y; Sone M; Inagaki N; Yamasaki T; Ogawa O; Takeda Y; Kurihara I; Umakoshi H; Ichijo T; Katabami T; Wada N; Ogawa Y; Yoshimoto T; Kawashima J; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Miyauchi S; Kamemura K; Fukuoka T; Yamamoto K; Otsuki M; Suzuki T; Naruse M;
J Clin Endocrinol Metab; 2018 Dec; 103(12):4456-4464. PubMed ID: 30165444
[TBL] [Abstract][Full Text] [Related]
6. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism.
Nishizaka MK; Zaman MA; Green SA; Renfroe KY; Calhoun DA
Circulation; 2004 Jun; 109(23):2857-61. PubMed ID: 15173035
[TBL] [Abstract][Full Text] [Related]
7. KCNJ5 mutation is a predictor for recovery of endothelial function after adrenalectomy in patients with aldosterone-producing adenoma.
Kishimoto S; Oki K; Maruhashi T; Kajikawa M; Mizobuchi A; Harada T; Yamaji T; Hashimoto Y; Yoshimura K; Nakano Y; Goto C; Yusoff FM; Nakashima A; Higashi Y
Hypertens Res; 2023 Sep; 46(9):2213-2227. PubMed ID: 37463983
[TBL] [Abstract][Full Text] [Related]
8. Comparison of biomarkers of endothelial dysfunction and microvascular endothelial function in patients with primary aldosteronism and essential hypertension.
Sang M; Fu Y; Wei C; Yang J; Qiu X; Ma J; Qin C; Wu F; Zhou X; Yang T; Sun M
J Renin Angiotensin Aldosterone Syst; 2021; 22(1):1470320321999491. PubMed ID: 33678006
[TBL] [Abstract][Full Text] [Related]
9. Decreased plasma prorenin levels in primary aldosteronism: potential diagnostic implications.
Berge C; Courand PY; Harbaoui B; Paget V; Khettab F; Bricca G; Fauvel JP; Lantelme P
J Hypertens; 2015 Jan; 33(1):118-25. PubMed ID: 25333683
[TBL] [Abstract][Full Text] [Related]
10. Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism.
Mantero F; Fallo F; Opocher G; Armanini D; Boscaro M; Scaroni C
Clin Sci (Lond); 1981 Dec; 61 Suppl 7():289s-293s. PubMed ID: 7032817
[TBL] [Abstract][Full Text] [Related]
11. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study.
Giacchetti G; Ronconi V; Turchi F; Agostinelli L; Mantero F; Rilli S; Boscaro M
J Hypertens; 2007 Jan; 25(1):177-86. PubMed ID: 17143190
[TBL] [Abstract][Full Text] [Related]
12. [Differences of blood plasma renin activity, angiotensin II and aldosterone levels in essential or secondary hypertension].
Song AL; Zeng ZP; Tong AL; Lu L; Chen S; Li M; Fu CL; Wang YH; Sun ML
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):294-8. PubMed ID: 22781950
[TBL] [Abstract][Full Text] [Related]
13. Effects of corticotropin-releasing factor (CRF) on aldosterone and 18-hydroxycorticosterone in essential hypertension and primary aldosteronism.
Miyamori I; Yasuhara S; Matsubara T; Okamoto S; Ikeda M; Koshida H; Morise T; Takeda Y; Takeda R; Vecsei P
Endocrinol Jpn; 1987 Dec; 34(6):809-19. PubMed ID: 2836182
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism.
Somlóová Z; Widimský J; Rosa J; Wichterle D; Strauch B; Petrák O; Zelinka T; Vlková J; Masek M; Dvoráková J; Holaj R
J Hum Hypertens; 2010 Oct; 24(10):625-30. PubMed ID: 20574447
[TBL] [Abstract][Full Text] [Related]
15. The role of biochemical tests and clinical symptoms in differential diagnosis of primary aldosteronism.
Prejbisz A; Postuła M; Cybulska I; Dobrucki T; Kabat M; Peczkowska M; Janas J; Janaszek-Sitkowska H; Makowiecka-Cieśla M; Januszkiewicz A
Kardiol Pol; 2003 Jan; 58(1):17-26. PubMed ID: 14502298
[TBL] [Abstract][Full Text] [Related]
16. Endothelial dysfunction is related to aldosterone excess and raised blood pressure.
Tsuchiya K; Yoshimoto T; Hirata Y
Endocr J; 2009; 56(4):553-9. PubMed ID: 19352049
[TBL] [Abstract][Full Text] [Related]
17. Clinical impacts of endothelium-dependent flow-mediated vasodilation assessment on primary aldosteronism.
Watanabe D; Morimoto S; Morishima N; Ichihara A
Endocr Connect; 2021 Jun; 10(6):578-587. PubMed ID: 33984834
[TBL] [Abstract][Full Text] [Related]
18. Elevation of angiotensin-II type-1-receptor autoantibodies titer in primary aldosteronism as a result of aldosterone-producing adenoma.
Rossitto G; Regolisti G; Rossi E; Negro A; Nicoli D; Casali B; Toniato A; Caroccia B; Seccia TM; Walther T; Rossi GP
Hypertension; 2013 Feb; 61(2):526-33. PubMed ID: 23248149
[TBL] [Abstract][Full Text] [Related]
19. Diurnal blood pressure pattern in patients with primary aldosteronism.
Zacharieva S; Orbetzova M; Elenkova A; Stoynev A; Yaneva M; Schigarminova R; Kalinov K; Nachev E
J Endocrinol Invest; 2006 Jan; 29(1):26-31. PubMed ID: 16553030
[TBL] [Abstract][Full Text] [Related]
20. Nocturnal, daytime, and postural changes of plasma aldosterone before and during dexamethasone in adenomatous and idiopathic aldosteronism.
Hoefnagels WH; Drayer JI; Smals AG; Benraad TJ; Kloppenborg PW
J Clin Endocrinol Metab; 1980 Dec; 51(6):1330-4. PubMed ID: 7440698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
